Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis

October 30, 2013 updated by: Jia-feng Wang, Changhai Hospital
Immunosuppression is the leading cause of death in septic patients. Neutrophils are classical components of innate immunology, but recent studies showed that neutrophils might display antigen presenting function and inhibit lymphocyte proliferation by expressing programmed cell death 1 ligand 1 (PD-L1). Whether neutrophils express PD-L1 and its role in immunosuppression during sepsis remain unclear.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

71

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients admitted in ICU at Changhai Hospital

Description

Inclusion Criteria:

  • patients with severe sepsis
  • patients with sepsis after PCNL for infectious kidney stone
  • patients with pancreatic cancer
  • healthy volunteers

Exclusion Criteria:

  • patients with immunodeficient diseases
  • patients who accept glucocorticoid or immunosuppressant
  • patients with an age older than 18 years
  • patients providing the informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Severe sepsis
Patients with severe sepsis
Infectious kidney stone
Patients with sepsis after PCNL for infectious kidney stone
Tumor
Patients with pancreatic cancer
Volunteer

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PD-L1 level on neutrophils
Time Frame: within 24h after recruitment
PD-L1 level on neutrophils was compared between different populations.
within 24h after recruitment

Secondary Outcome Measures

Outcome Measure
Time Frame
28-day mortality
Time Frame: 28 days after diagnosis of sepsis
28 days after diagnosis of sepsis

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Changhai Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2011

Primary Completion (Actual)

January 1, 2013

Study Completion (Actual)

January 1, 2013

Study Registration Dates

First Submitted

October 30, 2013

First Submitted That Met QC Criteria

October 30, 2013

First Posted (Estimate)

November 6, 2013

Study Record Updates

Last Update Posted (Estimate)

November 6, 2013

Last Update Submitted That Met QC Criteria

October 30, 2013

Last Verified

October 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NeutrophilPD-L1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe